Latest Nektar Therapeutics News & Updates

See the latest news and media coverage for Nektar. We track all announcements, press releases, and industry mentions in real time, all in one place.

Nektar Therapeutics (Nektar)

Biopharmaceutical company developing autoimmune and inflammatory therapies

nektar.com

Headquarters: San Francisco, United States
Founded year: 1990
Company type: Public company
Number of employees: 200–720
Industry: Pharmaceuticals

Last updated October 7

Latest news about Nektar Therapeutics (Nektar)

In short: Nektar received a $90 million jury verdict against Eli Lilly over a rezpegaldesleukin agreement

Company announcements

September 25 Nektar

Nektar wins $90m damages from Lilly

A jury found Eli Lilly breached a license agreement regarding rezpegaldesleukin. Nektar received the verdict subject to post-trial proceedings.

August 25 Nektar

Nektar announces positive Phase 2b atopic dermatitis results

The drug met all primary endpoints in adults with moderate-to-severe disease. These findings support ongoing Phase 3 clinical development.

August 13 Nektar

Nektar announces Q2 2026 financial results

Cash and investments total $1,023.4 million, up from $245.8 million at end of 2025. Net loss narrowed to $40.6 million, and cash runway extends to Q3 2028.

May 7 Nektar

Nektar Therapeutics reports Q1 2026 financial results

Cash reaches $731.6M. Revenue $10.9M, net loss $44.9M. Advances rezpegaldesleukin Phase 3 trials. Raises $373.8M in offering.

Media coverage

October 7 JD Supra

Nektar v. Lilly: Lilly Defeats CRE Claim, but Jury Finds It Owes $90M for Breaching the Implied Covenant of Good Faith and Fair Dealing

On September 24, 2026, after five days of deliberation, a federal jury in the Northern District of California found that Eli Lilly & Co.

September 19 Reuters

Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

A federal jury in California has determined that Eli Lilly must pay Nektar Therapeutics $90 million for breaking an agreement related to an autoimmune drug...

September 17 Ad Hoc News

Nektar Therapeutics stock gains after Q2 loss narrows

Nektar Therapeutics stock has climbed strongly in 2026, with shares closing at USD 68.36 on September 17, 2026 on Nasdaq. The company reported a Q2...

September 8 Law360

Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury

Eli Lilly & Co. breached its deal with Nektar Therapeutics to co-develop the autoimmune-disease drug Rezpeg and instead "sabotaged" its development in favor of a...

Never miss news about Nektar

Track Nektar and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nektar competitors & trending companies

Browse news for competitors to Nektar and other trending companies.